{
    "id": 20844,
    "fullName": "ZNF767 - BRAF",
    "impact": "fusion",
    "proteinEffect": "gain of function",
    "geneVariantDescriptions": [
        {
            "description": "ZNF767-BRAF results from the fusion of ZNF767 and BRAF, resulting in activation of Mapk signaling, cell transformation in culture, tumorigenesis in mouse models, and is associated with Raf inhibitor resistance (PMID: 28092667). ZNF767-BRAF has been identified in melanoma (PMID: 28092667).",
            "references": [
                {
                    "id": 14048,
                    "pubMedId": 28092667,
                    "title": "Oncogenic BRAF fusions in mucosal melanomas activate the MAPK pathway and are sensitive to MEK/PI3K inhibition or MEK/CDK4/6 inhibition.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28092667"
                }
            ]
        }
    ],
    "type": null,
    "gene": {
        "id": 79970,
        "geneSymbol": "ZNF767P",
        "terms": [
            "ZNF767P",
            "ZNF767"
        ]
    },
    "variant": "ZNF767 - BRAF",
    "createDate": "04/08/2016",
    "updateDate": "10/16/2019",
    "referenceTranscriptCoordinates": null,
    "partnerGenes": [
        {
            "gene": {
                "id": 673,
                "geneSymbol": "BRAF",
                "terms": [
                    "BRAF",
                    "B-raf",
                    "B-RAF1",
                    "BRAF1",
                    "NS7",
                    "RAFB1"
                ]
            }
        }
    ],
    "evidence": [
        {
            "id": 18841,
            "approvalStatus": "Preclinical - Patient cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, cells derived from a patient with primary mucosal melanoma harboring ZNF767-BRAF were resistant to CCT241161 in culture (PMID: 28092667).",
            "molecularProfile": {
                "id": 21341,
                "profileName": "ZNF767 - BRAF"
            },
            "therapy": {
                "id": 3106,
                "therapyName": "CCT241161",
                "synonyms": null
            },
            "indication": {
                "id": 50929,
                "name": "mucosal melanoma",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 14048,
                    "pubMedId": 28092667,
                    "title": "Oncogenic BRAF fusions in mucosal melanomas activate the MAPK pathway and are sensitive to MEK/PI3K inhibition or MEK/CDK4/6 inhibition.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28092667"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 18846,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Mekinist (trametinib) and Kisqali (ribociclib) combination treatment resulted in enhanced growth inhibition of melanoma cells expressing ZNF767-BRAF in culture and in xenograft models (PMID: 28092667).",
            "molecularProfile": {
                "id": 21341,
                "profileName": "ZNF767 - BRAF"
            },
            "therapy": {
                "id": 1974,
                "therapyName": "Buparlisib + Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 14048,
                    "pubMedId": 28092667,
                    "title": "Oncogenic BRAF fusions in mucosal melanomas activate the MAPK pathway and are sensitive to MEK/PI3K inhibition or MEK/CDK4/6 inhibition.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28092667"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 18838,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case study, Zelboraf (vemurafenib) treatment resulted in rapid disease progression in a patient with primary mucosal melanoma harboring ZNF767-BRAF fusion, and did not inhibit Mapk signaling or survival of cells derived from this patient in culture (PMID: 28092667).",
            "molecularProfile": {
                "id": 21341,
                "profileName": "ZNF767 - BRAF"
            },
            "therapy": {
                "id": 342,
                "therapyName": "Vemurafenib",
                "synonyms": null
            },
            "indication": {
                "id": 50929,
                "name": "mucosal melanoma",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 14048,
                    "pubMedId": 28092667,
                    "title": "Oncogenic BRAF fusions in mucosal melanomas activate the MAPK pathway and are sensitive to MEK/PI3K inhibition or MEK/CDK4/6 inhibition.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28092667"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 18844,
            "approvalStatus": "Preclinical - Patient cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Mekinist (trametinib) and Kisqali (ribociclib) combination treatment resulted in enhanced Parp cleavage and growth inhibition in cells derived from a patient with primary mucosal melanoma harboring ZNF767-BRAF in culture (PMID: 28092667).",
            "molecularProfile": {
                "id": 21341,
                "profileName": "ZNF767 - BRAF"
            },
            "therapy": {
                "id": 4472,
                "therapyName": "Ribociclib + Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 50929,
                "name": "mucosal melanoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 14048,
                    "pubMedId": 28092667,
                    "title": "Oncogenic BRAF fusions in mucosal melanomas activate the MAPK pathway and are sensitive to MEK/PI3K inhibition or MEK/CDK4/6 inhibition.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28092667"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 18840,
            "approvalStatus": "Preclinical - Patient cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, cells derived from a patient with primary mucosal melanoma harboring ZNF767-BRAF were resistant to CCT196969 in culture (PMID: 28092667).",
            "molecularProfile": {
                "id": 21341,
                "profileName": "ZNF767 - BRAF"
            },
            "therapy": {
                "id": 3105,
                "therapyName": "CCT196969",
                "synonyms": null
            },
            "indication": {
                "id": 50929,
                "name": "mucosal melanoma",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 14048,
                    "pubMedId": 28092667,
                    "title": "Oncogenic BRAF fusions in mucosal melanomas activate the MAPK pathway and are sensitive to MEK/PI3K inhibition or MEK/CDK4/6 inhibition.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28092667"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 18845,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Mekinist (trametinib) and Kisqali (ribociclib) combination treatment resulted in enhanced tumor growth inhibition in xenograft models of melanoma cells expressing ZNF767-BRAF (PMID: 28092667).",
            "molecularProfile": {
                "id": 21341,
                "profileName": "ZNF767 - BRAF"
            },
            "therapy": {
                "id": 4472,
                "therapyName": "Ribociclib + Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 14048,
                    "pubMedId": 28092667,
                    "title": "Oncogenic BRAF fusions in mucosal melanomas activate the MAPK pathway and are sensitive to MEK/PI3K inhibition or MEK/CDK4/6 inhibition.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28092667"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 18842,
            "approvalStatus": "Preclinical - Patient cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Mekinist (trametinib) inhibited Mapk signaling and survival in a dose-dependent manner in cells derived from a patient with primary mucosal melanoma harboring ZNF767-BRAF in culture (PMID: 28092667).",
            "molecularProfile": {
                "id": 21341,
                "profileName": "ZNF767 - BRAF"
            },
            "therapy": {
                "id": 2,
                "therapyName": "Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 50929,
                "name": "mucosal melanoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 14048,
                    "pubMedId": 28092667,
                    "title": "Oncogenic BRAF fusions in mucosal melanomas activate the MAPK pathway and are sensitive to MEK/PI3K inhibition or MEK/CDK4/6 inhibition.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28092667"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 18843,
            "approvalStatus": "Preclinical - Patient cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Mekinist (trametinib) and Buparlisib (BKM120) combination treatment resulted in enhanced Parp cleavage and growth inhibition in cells derived from a patient with primary mucosal melanoma harboring ZNF767-BRAF in culture (PMID: 28092667).",
            "molecularProfile": {
                "id": 21341,
                "profileName": "ZNF767 - BRAF"
            },
            "therapy": {
                "id": 1974,
                "therapyName": "Buparlisib + Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 50929,
                "name": "mucosal melanoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 14048,
                    "pubMedId": 28092667,
                    "title": "Oncogenic BRAF fusions in mucosal melanomas activate the MAPK pathway and are sensitive to MEK/PI3K inhibition or MEK/CDK4/6 inhibition.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28092667"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 18839,
            "approvalStatus": "Preclinical - Patient cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, cells derived from a patient with primary mucosal melanoma harboring ZNF767-BRAF were resistant to PLX8394 in culture (PMID: 28092667).",
            "molecularProfile": {
                "id": 21341,
                "profileName": "ZNF767 - BRAF"
            },
            "therapy": {
                "id": 1041,
                "therapyName": "PLX8394",
                "synonyms": null
            },
            "indication": {
                "id": 50929,
                "name": "mucosal melanoma",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 14048,
                    "pubMedId": 28092667,
                    "title": "Oncogenic BRAF fusions in mucosal melanomas activate the MAPK pathway and are sensitive to MEK/PI3K inhibition or MEK/CDK4/6 inhibition.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28092667"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 21341,
            "profileName": "ZNF767 - BRAF",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        
    ]
}